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ABSTRACT
Context: Rhodiola rosea L. (Crassulaceae) is well-known to contain flavonoids such as the herbacetin
derivative rhodiosin. However, flavonoids are not typically used in quality control.
Objective: This study analyses two flavonoids of R. rosea rhizomes and roots for their potential as analyt-
ical markers.
Materials and methods: Two constituents were isolated from ethanolic extracts via HPLC, identified via
NMR and quantified via RP-HPLC. Presence and content variation was investigated according to extraction
(solvent and repetitions), drying (temperature and duration) and sample origin (homogenously cultivated
plants of different provenance, commercial samples).
Results: Rhodiosin was identified as a main flavonoid, accompanied by 10-fold lower concentrated herba-
cetin. Both compounds were best extracted with 70–90% ethanol, but were also detectable in more
aqueous extracts. Different drying conditions had no effect on the flavonoid content. These two flavo-
noids were consistently identified in rhizome and root extracts of over 100 R. rosea samples. Rhizomes
tend to contain less flavonoids, with average ratios of rosavins to flavonoids of 1.4 (rhizomes) and 0.4
(roots). Provenance differences were detected in the range (rhodiosin plus herbacetin) of 760–6300 mg/mL
extract corresponding to a maximum of approximately 0.5–4.2% (w/w) in the dry drug.
Conclusions: For the first time, two main flavonoids present in R. rosea were quantified systematically.
Rhodiosin and herbacetin can be detected simultaneously to phenylpropenoids or salidroside in authentic
samples, influenced by the plant part examined and the plant origin. Rhodiosin and herbacetin may serve
as additional marker to guarantee a consistent content of R. rosea products.
ARTICLE HISTORY
Received 13 June 2018
Revised 21 November 2018
Accepted 15 January 2019
KEYWORDS
HPLC; flavonoid
Introduction
Rhodiola rosea L. (Crassulaceae) is one of the well-known plants
of a group of so-called adaptogens. Derived products are used
for various medicinal purposes linked to stress-related acute
and chronic conditions, including mental and physical perform-
ance, ageing and cancer development (Chiang et al. 2015).
Pharmacopoeia-specified standardization of products currently
focuses on salidroside, a phenylethanoid found in all species of
the Rhodiola genus besides some other plant species, as well as
on phenylpropenoids characteristic of R. rosea and typically
expressed as total rosavins.
Other constituents of Rhodiola species have occasionally been
suggested to potentially contribute to pharmacological activities
including the aglycon of the phenylpropenoids cinnamyl alcohol
(CA) (Peschel et al. 2016), monoterpene glycosides such as rosir-
idin (van Diermen et al. 2009), gallic acid derivatives such as epi-
gallocatechin-3-gallate (Chen et al. 2015) or lignans and some
flavonoids including rhodiosin (1) (Zhou et al. 2015).
Flavonoids are common constituents of many herbal drugs,
present mainly in traditional extracts using ethanol/water mix-
tures. Their reasonable stability and easy detection often make
them the parameter of choice for standardization. Several
flavonoids have been isolated from Rhodiola species and have
been reported previously. These include herbacetin and its glyco-
sides including 3,7-dimethylherbacetin, rhodiosin (herbacetin-7-
O-glucorhamnoside), rhodionin (herbacetin-7-O-a-L-rhamnopyr-
anoside), rhodalgin (herbacetin-8-O-a-L-arabinopyranoside), rhodioni-
din (herbacetin-7-O-a-L-rhamnopyranosyl-8-O-b-D-glucopyranoside),
rhodalin (herbacetin-8-O-b-D-xylopyranoside), rhodalidin (herba-
cetin-3-O-b-D-glucopyranosyl-8-O-b-D-xylopyranoside), rhodiolin
(a flavolignan of herbacetin); tricin and its glycosides, as well as
the gossypetin glycosides rhodiolgin (gossypetin-7-O-L-rhamno-
pyranoside) and rhodiolgidin (gossypetin-7-O-a-L-mannopyrano-
sil-8-O-b-D-glucopyranoside) (Kurkin et al. 1982, 1984a, 1984b;
Zapesochnaya and Kurkin 1983; Zapesochnaya et al. 1985).
Regarding R. rosea, the isolated flavonoids are usually glyco-
sides of kaempferol, gossypetin and herbacetin (2). In total,
approximately 20 flavonoids have been described from this spe-
cies, including tricin, herbacetin, gossypetin and their glycosides
found in leaves/flowers/aerial parts, as well as flavonolignans and
herbacetin found in underground parts, i.e., in rhizome or root
(Zapesochnaya and Kurkin 1983; Zapesochnaya et al. 1985).
While some flavonoids, e.g., herbacetin are present in several
families (e.g., Asteraceae, Gnaphilieae, Linaceae, Lauraceae,
Atripliceae) (Wollenweber et al. 1997; El-sayed et al. 1999;
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Stewens et al. 1999; Fliniaux et al. 2014; Wei et al. 2017) others
seem to be typical for Rhodiola species. These specific com-
pounds, including rhodionin and rhodiosin, possess a specific
sugar moiety such as the 3-O-b-D-glucopyranosyl-L-rhamnopyra-
nose residue named ‘rhodiose’ after the first isolation works in
Russia in the 1980s (Kurkin et al. 1982; Zapesochnaya and
Kurkin 1983).
Like other flavonoids, herbacetin and derivatives show in vitro
and in vivo effects that are linked to the multiple hydroxyl
groups responsible for radical scavenging properties (Kwon et al.
2009; Qiao and Liu 2013) and associated with unspecific effects
on membrane structures and enzyme activities related to cancer
genesis and progression (Nakamura et al. 2007; Hyuga et al.
2013; Qiao et al. 2013), metabolism (Kobayashi et al. 2008) and
other physiological and/or pathological processes (Jeong et al.
2009; Li et al. 2015, 2016).
While flavonoids in R. rosea are known, their quantity was
never investigated in view of more unique and interesting char-
acteristic constituents such as rosavin or salidroside. Hence, typ-
ical extracts for medicinal use have never been systematically
studied in this regard either. In fact, flavonoids may not only
contribute to some activities, but also give an additional analyt-
ical option to guarantee identity, purity and consistent content
of medicinal products. Therefore, our research focused on identi-
fying two main peaks with flavonoid UV spectra as potentially
characteristic for R. rosea extract fingerprints following indicators
from our previous studies. These two substances were isolated
via HPLC and their structures were determined by NMR analysis
and compared with literature data. We aimed to extend and val-
idate a previously described HPLC method for the quantitative
analysis in order to study the influence of extraction solvent,
plant part, drying process and drug origin (different plant prove-
nances, marketed drugs and products) on the flavonoid content.
The overall goal of our study was to get a quantitative overview
of the main flavonoids present in R. rosea in comparison to the
conventional standards salidroside and rosavins.
Materials and methods
Plant and reference materials
Rhizome, root and herb samples were obtained from own cultiva-
tion as previously described (Peschel et al. 2016, 2018). Plants ori-
ginate from diverse natural habitats, and voucher specimens have
been deposited at the herbarium of the Biologiezentrum der
Ober€osterreichischen Landesmuseen (Linz, Austria).
Marketed commodities including four dried herbal drugs (I:
‘Rhizomata et radices Rhodiolae rosea’, 50 g cut pieces, Barnaul,
Russia; II: unlabeled drug from a market stand, 40 g cut pieces,
Barnaul, Russia; III: ‘Rhodiola rosea (rhizoma)’, 50 g cut pieces,
Gorno-Altaisk, Russia; IV: ‘Rhodiolae radix concisus’, 500 g,
Gittelde, Germany) and two products (I: Rhodiola rosea extract,
36.7 g/100 g powder in capsules, Germany); II: ‘Arctic root –
Rhodiola rosea’, powder in capsules, originating from UK/sold
in Szeged, Hungary) were studied. For the quantitative HPLC
analysis, rhodiosin was purchased from Carbosynth
(Compton, UK) and herbacetin was purchased from Phytolab
(Vestenbergsgreuth, Germany).
Processing and extraction
Plants were harvested, separated into different plant parts, cut,
dried, stored, powdered and extracted as previously described
(Peschel et al. 2013, 2016, 2018). Experimental variations in
extraction/drying procedures or sample processing are explained
below. The routine sample preparation for the quantitative ana-
lysis involves the following parameters: cutting before drying
(2–6 cm, maximum 1 cm thick); drying temperature: 45 C; dry-
ing duration: 6 days; powder particle size before extraction:
0.8–0.15mm; extraction solvent: 70% ethanol (EtOH); drug to
solvent ratio: 1:5; 5 days maceration at room temperature with
shaking for 2 h at start and another 30min at the end, followed
by centrifugation.
Isolation of flavonoids
For the isolation of flavonoids, 70% EtOH extracts of rhizome/
root were combined. The isolation process was carried out using
a Waters HPLC system comprising a Waters W600 pump, a
W600 controller and a Waters 2487 dual channel UV detector,
controlled by Empower software. A Kinetex XB-C18, (5 mm,
250 4.6mm) column was used as the stationary phase. The
mobile phase consisted of water (A) and acetonitrile (B). Elution
was started with 83% A/17% B (1min), then it was changed to
72% A/28% B (10min) and to 50% A/50% B (5min), followed
by methanol washing for 5min and another 5min equilibration
with the starting eluent. At 12 and 13min, two main peaks were
detected with UV spectra characteristic to flavonoids (UV kmax
274, 328, 380 nm and 274, 328, 380 nm, respectively). These com-
pounds were isolated by the HPLC method described above.
Samples containing remarkable amounts of these compounds
were pooled, evaporated and re-dissolved to gain a solution con-
taining approx. 10mg/mL of the index compounds. Forty injec-
tions (20 mL each) were carried out and the two peaks were
separately collected. The purity of these two fractions was con-
firmed by HPLC and the identity of the evaporated compounds
was elucidated by NMR.
Identification of the isolated flavonoids
NMR spectra were recorded in methanol-d4 on a Bruker Avance
600 III spectrometer (1H: 600.13MHz; 13C: 150.9MHz) equipped
with a 5mm cryo-TXI probe. The peaks of the residual solvent
(dH 3.31; dC 49.00) were taken as reference points. Chemical
shifts are expressed in parts per million, and coupling constants
(J) values are reported in Hz. Data were acquired and processed
with the MestReNova v6.0.2-5475 software.
Compounds 1 and 2 were identified as rhodiosin and herba-
cetin, respectively, based on the comparison of their 1H and 13C
spectral data with those in the literature (Nawwar et al. 1984;
Jeong et al. 2009).
HPLC quantitative analysis and validation
Rhodiosin (1) and herbacetin (2) were determined by external
standard calibration using HPLC equipment, conditions and
assay previously described, with an extension of running time
and detection to 37min (Peschel et al. 2016). Peaks were well
separated and showed similar UV/VIS spectra (1: tR 35.5min,
UV kmax 274, 328, 380 nm; 2: tR 36.2min; UV kmax 274, 328,
380 nm). As the most suitable wavelength, UV k¼ 254 nm was
chosen for the analysis. Concentrations of 1 and 2 were deter-
mined in duplicate from three samples each, and expressed in
lg/mL macerate (mean ± SD, N¼ 3). Experimental variations (if
any) are given below.
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Validation
Limits of detection (LOD) and quantification (LOQ) were eval-
uated by the Shimadzu# LabSolutions (version 5.82) software.
Precision was checked by repeated measurements of standards at
a medium (100lg/mL) concentration on the same day (intra-
assay precision) and on three different days (inter-assay preci-
sion) (for R.S.D values see Table 1). Linearity was determined
using six different concentrations per reference standard in the
range of 6.16–308.0 lg/mL for 1 and 3.44–172.0 lg/mL for 2,
with a linear relationship as given in Table 1. Accuracy was
checked by spiking of a flavonoid-low extract with 50%, 100%
and 150% of the native amounts of 1 and 2.
Derived parameters
Besides the absolute values of 1 and 2 (lg per mL liquid hydroe-
thanol extract), we have also calculated the sum of both flavo-
noids (FLAVtot) and the ratio of flavonoids to phenylpropenoid,
as well as the ratio of flavonoids to phenylethanoid compounds
which are usually used for the standardization of R. rosea; these
ratios served as relative parameters. Corresponding data for rosa-
vins (expressed as ROStot: sum of rosavin, rosarin and rosin) and
their aglycon trans-CA (PPtot: total phenylpropenoids¼ total
rosavins þ CA), as well as for salidroside and its aglycon
(SALtot, sum of salidroside and tyrosol) were available and
reported previously (Peschel et al. 2016, 2018).
For a comparison with literature data, we have also estimated
the approximate amount of 1 and 2 in the original herbal drug
(% w/w in the dry drug) based on the yield of the extraction
process (see below) and on the drug to solvent ratio (% w/w
flavonoids in dry drug¼ x mg/mL 1.33 5mL/g/10). For
example, a tincture containing 1.0mg/mL flavonoids approxi-
mately corresponds to a maximum of 0.66% flavonoids (w/w) in
the original dry drug.
Influence of solvent and extraction procedure
Influence of solvent polarity
Five different extracts were prepared (N¼ 3) using water, EtOH
30%, 50%, 70% and 90% v/v, respectively (all of analytical grade,
Molar Chemicals, HU) for three drug samples of the same prov-
enance (rhizome of a 4-year-old plant, UK cultivation; rhizome
and root of a 6-year-old plant, Austrian cultivation) and flavon-
oid content was expressed in lg/mL (mean± SD, N¼ 3).
Extraction process repetition
In order to check how efficient and exhaustive a single extraction
process is, it was repeated thrice. The same three samples (two
rhizome, one root) using four different extraction solvents
(3 30% EtOH, 3 50% EtOH, 3 70% EtOH, 3 90% EtOH)
were after the first extraction (M1) additional three times
(M2–4) macerated with fresh solvent after filtering and drying
the drug sample following the first and each following extraction.
1 and 2 contents (mean ± SD of measurement in duplicate of
three samples each) of all four repetitions were compared.
Influence of plant part used
From three authentic provenances (RR-I, RR-II, RR-III) and a
previously identified non-authentic provenance (hybrid R-IV),
three 5-year-old plants (three individual plants, each cultivated
in the UK and harvested in July) were split into herb, rhizome
and root, dried at 45 C, ground (mesh diameter: 0.8–1.5mm)
and 5 g of each sample was finally extracted with 25.0mL 70%
EtOH for 5 days (see above). Contents of 1 and 2 were deter-
mined and expressed in lg/mL macerate (mean ± SD, N¼ 3).
Influence of the drying procedure
Drying temperature: Two 5-year-old plants from five randomly
chosen provenances (I–V, 7-year-old plants, cultivated in
Austria, harvested in July) were split into rhizome and root.
Each of the cut samples (2–6 cm, maximum 1 cm thick) were
halved; one half was dried at 45 C and the other one at 65 C
using warm air ventilation for 5 days, yielding four root and
four rhizome samples at each temperature per provenance. Dry
samples were ground and extracted as described above. Contents
of 1 and 2 were determined and expressed in lg/mL macerate
(mean ± SD of two plants, two samples each, N¼ 4).
Drying duration: Two 4-year-old plants from two randomly
chosen provenances (VI–VII, 6-year-old plants, Austrian cultiva-
tion, harvested in October) were split into rhizome and root.
Each sample was halved; one half was cut into smaller pieces
(1–4 cm, maximum 0.5 cm thick) and the other half was cut into
bigger pieces (3–8 cm, maximum 1.5 cm thick). All samples were
split again, yielding four root and four rhizome samples for both
sizes per provenance. Samples were dried at 20 C at moderate
air ventilation (fine-cut samples: 10 days, coarse-cut samples:
30 days). Dry samples were ground and extracted as described
above. The content of 1 and 2 was determined and expressed in
lg/mL macerate (means ± SD, N¼ 4).
Influence of drug origin – commodities of commerce
Four marketed herbal drug samples (drug I–IV) and two prod-
ucts (prod I, II) were extracted as described above. In case of the
commercial products, the powdered content of the capsules was
directly used for extraction regardless of the excipients or any
other possible ingredients contained. For each sample, two mac-
erates were prepared and measured in duplicate.
Influence of drug origin – plants of different provenances
Roots and rhizome samples from 9-year-old cultivated plants of
18 provenances (p01–p17 authenticated R. rosea, p18 an
unknown species) and two wild alpine plants of unknown age
Table 1. Validation data for quantitative determination of rhodiosin (1) and herbacetin (2).
R2 Regression equation Range (mg/mL) LOD (lg/mL) LOQ (lg/mL) R.S.D.a (%, n¼ 6) R.S.D.b (%, n¼ 6)
Rhodiosin 0.9989 y¼ 2Eþ 06x – 151221 0.00616–0.308 47.02 156.72 0.28 0.41
Herbacetin 0.9958 y¼ 2Eþ 06xþ 336128 0.00344–0.172 7.60 25.35 1.38 2.47
aIntra-assay precision within one analytical run 6 injections.
bBetween-assay precision at three different days (each sample in duplicate).
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(p19, p20) from the Eastern Alps were previously described and
studied focusing on rosavins, CA and salidroside contents
(Peschel et al. 2018). We grouped and analysed data as follows:
(a) the average of the whole sample matrix of cultivated authen-
tic R. rosea from 17 provenances, (b) means (N¼ 3,±S.E.M.) of
all provenances (N¼ 20) and (c) means of five provenance
groups: North Western European Islands (NW; N¼ 4), North
Eastern Europe (NE, N¼ 3), Alps/Pyrenees (ALP/PYR; N¼ 6),
Southern Siberia (ALTAI, N¼ 4), plus the two provenances from
the Eastern Alps (wild Alp). The experimental design, sampling
and analysis have been described previously (Peschel et al. 2018).
Statistical analysis
N values for 1 þ 2 were calculated as means of HPLC measure-
ments carried out in duplicate. All samples tested were prepared
in triplicate (with few exceptions prepared in duplicate only),
and results were calculated as mean± SD per treatment/variable
factor. For provenance comparison, means ± S.E.M. were calcu-
lated for (I) all individual plants (N¼ 51), (II) three individual
plants of each genotype (N¼ 17) and (III) five geographical
region groups with divergent N. For geographical region groups,
significance was tested for each compound parameter using two-
way ANOVA with or without Tukey’s post-test (R-3.2.1 soft-
ware) and results are indicated with different letters for those
groups with p< 0.05.
Results and discussion
Isolation, identification and assays of 1 and 2
The isolation procedure using a dry pooled extract (root plus
rhizome) yielded 5.24mg of 1 and 3.41mg of 2. Preliminary
identification of the compounds was carried out by comparing
the UV spectra of 1 and 2 with analytical standards. Structure
validation was carried out via NMR analysis using a Bruker
Avance 600 III spectrometer (1H: 600.13MHz; 13C: 150.9MHz).
Although the presence of several other flavonoids has been
reported for Rhodiola species previously, we focused on 1 and 2
for possible quantitative analysis (Figure 1).
Via the extension of our previously described HPLC method
(Peschel et al. 2016), 1 and 2 (tR: 35.5 36.2min, respectively,
Figure 2) could be detected baseline-separated from other peaks.
Despite a prolonged run time of the analysis, simultaneous
detection to rosavins and salidroside is advantageous for a HPLC
fingerprint, as well as for quantitative determination.
Regarding the assay, detection may be accomplished at several
wavelengths including 254 nm (used for rosavins and CA detec-
tion) and 275 nm (used for salidroside and tyrosol detection)
without major differences in results despite baseline deviations.
Precision, linearity and accuracy were checked for both 254 nm
and 275 nm detections (Table 1). The LOD was 47.02 lg/mL and
7.60 lg/mL for 1 and 2, respectively, with a signal to noise ratio
of 3. The LOQ was 156.72lg/mL and 25.35 lg/mL, respect-
ively, with a signal to noise ratio of 10. Recovery rates were
84.66, 89.51 and 93.25% for 1 and 56.42, 64.99 and 75.54% for 2
at 50, 100 and 150%, respectively.
Extraction of 1 and 2
Traditional Rhodiola tinctures and dry extracts used in contem-
porary products are commonly based on hydro-ethanol extrac-
tion. Regarding the tested range of five solvents, the flavonoids
of interest were best extracted with 70–90% EtOH, slightly less
with 50% EtOH and considerably less with 30% EtOH (Figure
3). Flavonoids were still detectable in pure aqueous extracts, but
were below the LOQ in our setting (not included in graph).
These findings suggest that commonly available extracts (40–70%
EtOH) should contain detectable amounts of flavonoids besides
rosavins and salidroside, but these may not be optimally
extracted. We used 70% EtOH for our screening, which is gener-
ally used for an optimized phenylpropenoid yield as previously
reported. We found a higher flavonoid content in roots than rhi-
zomes independent of the extraction solvent, while phenylprope-
noids were found to be less concentrated in the roots (Peschel
et al. 2016).
Using 70–90% EtOH, approximately 75% of the total extract-
able amount was obtained in a single extraction process (5-day
maceration). A nearly exhaustive extraction was reached with
two follow-up macerations. A fourth repetition did not yield
relevant extra amounts (<1% of total yield) and was often below
the LOQ. These data indicate that for the maximum extraction
of 1 and 2 from dried plant samples 70–90% EtOH and 2–3
repeated extractions may be appropriate, allowing to determine
the total flavonoid content which could be suitable, e.g., for plant
characterization or root/rhizome assays for pharmaceutical start-
ing materials or powdered drugs directly used in commercial
products. For our screening purpose, the single maceration,
yielding consistently about 75% of the total flavonoid content
was considered to be suitable to compare the 70% EtOH extracts
of tested samples.
Flavonoid content of different plant parts
The flavonoid content of the herb was found to be rather low
(<400lg/mL in the extract, corresponding to cca. 0.2% in the dry
drug) compared to rhizome and root, whose extracts usually con-
tained at least 1800–2400lg/mL of flavonoids (corresponding to
1.2–1.6% in dry drug) for our sample set (Figure 4). Irrespective of
Figure 1. Structure of rhodiosin (1) and herbacetin (2).
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the plant part analysed, both 1 and 2 are always detected, and 1 is
usually 5- to 10-fold concentrated compared to 2.
A hybrid accession (R-IV) previously described as having
deviating morphological characteristics and exceptionally low
amounts of phenylpropenoids (Peschel et al. 2013, 2016) also
contained 1 and 2 in the rhizome in lower concentrations
than in the authentic provenances. Consequently, testing sim-
ply for the presence/absence of 1 and 2 (as a qualitative
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Figure 2. HPLC chromatogram (k¼ 254 nm) for the simultaneous determination of 1 and 2 alongside characteristic phenylpropenoids in R. rosea (1, rhodiosin; 2, her-
bacetin; 3, rosarin; 4, rosavin; 5, rosin; 6, cinnamylalcohol). (A) Authentic R. rosea rhizome; (B) authentic R. rosea root; (C) non-identified Rhodiola species root.
PHARMACEUTICAL BIOLOGY 299
fingerprint) may not be suitable for identification of the spe-
cies; however, when quantified, particularly low amounts of
flavonoids can indicate quality issues such as admixtures of
other Rhodiola species. In contrast to other root/rhizome com-
parisons in this study, amounts of 1 and 2 were largely equal
in both plant parts, while elsewhere root extracts exhibited
often more than double the amount than rhizome extracts.
Reasons for these differences are not obvious, but this phe-
nomenon might be linked to a deviating cultivation site and
harvest time.
Influence of the drying procedure
Different temperatures applied during drying (45 versus 65 C
for 5 days), as well as different drying durations according to cut
size (10 days versus 30 days at room temperature) did not affect
the flavonoid content (Figure 5). Contents of 1 and 2 were more
influenced by plant provenance and the plant part used. The
largely consistent ratios of 1 and 2 also suggest that both flavo-
noids are stable and are not affected by drying temperature or
potential post-harvest enzymatic degradation.
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Figure 3. Influence of the extraction solvent on extraction efficiency. Contents of 1 and 2 in rhizome (A, B) and root samples (C), each extracted with four different
solvents and three successive macerations M1–M3 (n¼ 3 each, mean± SD).
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Figure 4. Flavonoid concentrations in 70% EtOH extracts from rhizome, root and herb of four different provenances (N¼ 3 each, mean± SD).
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Flavonoid content of marketed commodities
In all samples of marketed Rhodiola drugs and products 1 and 2
were detected in very different quantities (Figure 6). For a better
comparison of extract profiles, the flavonoid content is presented
alongside previously determined contents of rosavins, CA and sali-
droside. Three drug samples originating from Russian markets and
shops containing a visibly major rhizome portion showed similar
profiles. In contrast, the drug sold as Rhodiolae radix concisus had
lower amounts of 1 and 2 (less concentrated than salidroside), but
most obviously it contained no phenylpropenoids. This finding
confirms that ‘Rhodiolae radix’ does not equal ‘Rhodiolae roseae
rhizoma et radix’, and that other Rhodiola species are also marketed
without specifying the exact species. Also product I (a mixture of
powder and a 70% EtOH extract) was found to have a moderate
flavonoid content, whereas product II showed very low amounts of
1, 2 and phenylpropenoids, but a high salidroside content. In this
case, it is assumed that R. rosea is only a minor part of the active
substance, while either salidroside is added or other Rhodiola spe-
cies prevail despite the product being labelled as R. rosea.
Flavonoid content in homogenously cultivated plants of
different provenances
On average, rhizome and root extracts of 51 simultaneously har-
vested 9-year-old plants (cultivated in the Eastern Alps) from 17,
mainly European provenances contained 1800 and 3100 mg/mL
flavonoids, respectively (Table 2). This means that our extraction
method yielded rhizome extracts with slightly more species-char-
acteristic rosavins than flavonoids, while root extracts contained
more flavonoids than rosavins. Since phenylpropenoid values
(ROStot þ CA) are usually higher in rhizomes than in root, as
previously reported, the ratio of rosavins to flavonoids differ sub-
stantially between these two plant parts (1.4 and 0.4, respect-
ively). Notably, in our 70% EtOH extracts the quantities of
flavonoids usually surpass those of salidroside, the common
standardization parameter for all Rhodiola species.
As per provenance, mean flavonoid values were in the range
of 760–3800 mg/mL in rhizomes and 880–6300 mg/mL in roots
(Figure 7). Thus, 1 þ 2 (with a consistent ratio of about 10:1)
were detected in all cultivated provenances and in those collected
from the wild. They were also found, but in lower amounts, in
the root extracts of the unidentified species p18, albeit with a
divergent ratio of 1 and 2 (1.6:1). Provenances with a particularly
high flavonoid content in rhizome (>2000 mg/mL) or root
(>3000 mg/mL) or in both, originate from diverse locations such
as the Pyrenees (p03), the Alps (p14), NW European Isles (p01,
p02, p05) and Russia (p04, p07). Also those with a lower flavon-
oid content (1000 mg/mL in rhizome or 2000 mg/mL in root)
are from different habitats: Southern Siberia (p12, p16), Finland
(p16) and all cultivated and collected plants from the Alps (p06,
p10, p11, p13, p19, p20).
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Figure 5. Flavonoid concentrations in rhizome and root extracts (70% EtOH) according to (Aþ B) drying temperature for five different provenances (I–V) and (C) dur-
ation of drying for two different provenances (VI–VII) (N¼ 3 each, mean± SD).
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Despite such diversity found according to regional groups, the
rhizomes and roots of R. rosea of NW European origin con-
tained significantly more flavonoids than any of the other four
groups (Figure 8). In Alpine provenances, it was generally low,
but mean values were affected by two obvious high-flavonoid
outliers from the Pyrenees and Swiss Alps. It suggests that prov-
enance does play a role, i.e., plant genetics might influence the
flavonoid content. However, the groups arbitrarily formed
according to the main geographical area of origin may not be
suitable alone to predict flavonoid contents. More provenances,
ideally of the same age and cultivated under equal conditions,
are required to confirm the trends observed here. Local variants
with particularly high or low quantities of flavonoids can
be assumed.
In order to understand the relevance of flavonoid quantifica-
tion for analytical standardization, we compared the amounts of
the two measured flavonoids with the levels of phenylpropenoids
(rosavins plus aglycon CA) and salidroside (plus aglycon tyrosol)
(Figure 8). For all regional groups the flavonoid content of
rhizome extracts was in a similar range as that of rosavins
(PPtot/FLAVtot ratio 0.9–1.8). In root extracts, flavonoids had at
least double amounts of rosavins across all cultivated geograph-
ical sources with the exception of the plants collected from the
wild (PPtot/FLAVtot ratio 0.3–1.2).
These results emphasize the relevance of rhizome/root por-
tions in a given drug. Nonetheless, the ratios of flavonoids to
other compounds currently used for quality assurance are rea-
sonably consistent within the whole species, and also as per
genotype. Hence, the analysis of flavonoids is to certain extent
an indicator for the whole phenolic spectrum. Our data suggest
that a sample of underground parts containing less than 500 mg/mL
of 1(þ2) in a derived 70% EtOH extract (corresponding to about
0.33% in the dry drug) is unlikely to be R. rosea or of otherwise
compromised quality.
The relative variation of the main characteristic constituents
according to rhizome/root proportion and provenance is also an
important issue to understand the possible divergent effects
reported in pharmacological or clinical studies. Summarizing our
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Figure 6. Concentrations of 1 and 2 in 70% EtOH extracts from marketed commodities (four dried herbal drugs and two products) of different origin, also showing
their content in rosavins (ROStot), cinnamyl alcohol (CA) and salidroside (SALtot) (N¼ 2, mean± SD).
Table 2. Content of 1 and 2 in 70% EtOH extracts from rhizomes and roots of R. rosea cultivated at 1580 m in Eastern Austria (n¼ 3, mean ± S.E.M., range of 51
samples across provenances p01–p17 harvested in May year 9).
Rhizome Root
Mean
(±S.E.M.)
Range
(min–max)
Mean
(±S.E.M.)
Range
(min–max)
Rhodiosin (1)
(lg/mL)
1586
(±211)
159–4885 2817
(±450)
216–8606
Herbacetin (2)
(lg/mL)
211
(±20)
53–547 308
(±34)
69–862
FLAVtot (1 þ2)
(lg/mL)
1797
(±230)
220–5431 3125
(±482)
285–9468
ROStot
a
(lg/mL)
1842
(±207)
530–4273 980
(±118)
361–2494
PPtot
b
(lg/mL)
2189
(±239)
729–5460 1236
(±140)
390–2844
SALtot
c
(lg/mL)
547
(±123)
112–3079 332
(±75)
54–1503
ROStot/FLAVtot ratio
(x:1)
1.39
(±0.25)
0.30–4.84 0.44
(±0.09)
0.10–1.54
SALtot/FLAVtot ratio
(x:1)
0.41
(±0.17)
0.06–4.91 0.21
(±0.14)
0.01–4.05
Comparison to previously detected phenylpropenoids and phenylethanoids plus derived ratios.
aROStot¼ rosavinþ rosarinþ rosin.
bPPtot¼ ROStotþ aglycon cinnamyl alcohol (CA).
cSALtot¼ salidrosideþ aglycon tyrosol.
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new results for flavonoids with our previous findings (rosavins
and salidroside), it becomes clear that although comparing
‘Rhodiola’ with ‘Rhodiola’ may often appear seemingly the same,
in fact, without the specified content of all three compound
classes it is not clear which main substance group biological sys-
tems are mostly exposed to. In some cases prevail rosavins (e.g.,
70% rhizome extract from a specific provenance of R. rosea). In
other cases, flavonoids (e.g., 70% root extract from a specific
provenance) or salidroside (e.g., a 30% extract from a Rhodiola
species other than R. rosea) may dominate the tested drug or
product and thus the pharmacological effects (Peschel et al.
2013, 2016, 2018).
Overall range of flavonoid content
Our results show remarkably high flavonoid values in 70–90%
EtOH extracts from rhizome and in particular, from roots of
authentic R. rosea. Quantities are comparable or superior to the
usual standards rosavins and salidroside, and are in the upper
range of scarce previous reports. Whether similar results are
obtained with different sample sets, extracts and analytical meth-
ods remains to be investigated. The first report on quantitative
differences between roots (range 0.2–0.45%) and rhizomes
(0.08–1.2%) of R. rosea came from cultivation tests in Finland,
however, without specifying the flavonoids. The flavonoid con-
tent of hairy roots was found to be three times higher than that
of rhizomes, and showed a decreasing trend with increasing fer-
tilization (Galambosi 2006).
Later studies usually refer to ‘roots’ with assumed diverse
mixtures of roots and rhizomes. Reported quantities for single
flavonoids vary, as do species provenance, plant part, and extrac-
tion solvent (when information is available). Data are mostly
obtained in the context of isolation and identification works but
not from validated quantitative analysis. Overall, 1 is typically
the main finding alongside 2, rhodionin and kaempferol. Reports
are available on isolations of 1 (19mg/g) and rhodionin (17mg/g)
from ‘root’ (80% EtOH extract) (Kwon et al. 2009), of 1
(1.7–2.5mg/g), rhodionin (0.14–0.3mg/g), 2 (0.51–1.5mg/g) and
kaempferol (0.78–1.5mg/g) from ‘root’ (unspecified extract) (C.
Ma et al. 2013) and later of 1 (22.9mg/g), rhodionin (13.3mg/g),
2 (5.5mg/g) and kaempferol (6.9mg/g) from ‘root’ (unspecified
extract) (Ma et al. 2014). Roots of R. sachalinensis were also
investigated and 1 (7.13mg/g) alongside rhodionin (3.98mg/g),
kaempferol (8.94mg/g), afzelin (2.82mg/g), multiflorin B
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Figure 7. Concentrations of 1 and 2 in roots and rhizomes of 17 provenances of R. rosea cultivated at 1580 m in Eastern Austria (p01–p17, N¼ 3, mean±S.E.M. har-
vested in year 9), as well as in p18 (unknown Rhodiola species) and p19/p20 (R. rosea of unknown age from wild collection) used as comparators. Provenances are
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(1.0mg/g) and kaempferol-3,40-di-O-b-D-glucopyranoside
(0.4mg/g) were detected in the dry extract (80% acetone) (Choe
et al. 2012). Another study reported quantities of rhodionin in
the range of 0.04–5.7mg/g (methanol/EtOAc from ‘roots and
rhizomes’) in 14 Asian Rhodiola species (R. rosea not included)
without information on the content of other flavonoids (Li and
Zhang 2008). Furthermore, overground parts of R. rosea showed
1 and 2 among 15 gossypetin, kaempferol, and quercetin glyco-
sides (Petsalo et al. 2006). In summary, while 1 does not appear
to be unique neither to the species R. rosea, nor to any of the
plant parts, its general appearance and quantitative prevalence
suggest that it could serve as a potential quality marker for
Rhodiolae roseae rhizoma et radix. We assume that the subordi-
nated aglycon herbacetin is a natural co-constituent of the plant
rather than an artefact originating from drying, extraction or
analytical processing. Based on our method no other flavonoids
such as rhodionin or kaempferol were identified in our rhizome
and root extracts of R. rosea.
Conclusions
This is the first systematic study focusing on occurrence and
amount of 1 and 2 in R. rosea drugs and preparations. 1 and 2
were best extracted with 70–90% EtOH, but are also detectable
in more polar extracts. Variations in drying conditions did not
influence the flavonoid content. We have consistently found 1
and 2 in over 100 samples of authentic R. rosea with major
quantitative differences between rhizome and root, and influ-
enced by plant origin despite equivalent age and growing condi-
tions. To a lesser extent and in different ratios they were also
found in 3 non-confirmed Rhodiola species, as well as in mar-
keted commodities that are unlikely to contain R. rosea as a
main source plant.
Flavonoids 1 and 2 can be detected simultaneously to phenyl-
propenoids and salidroside, often in concentrations higher than
those. A gene pool of 20 provenances showed partially significant
differences in the flavonoid (1 and 2) content within the overall
range of 760–6300 mg/mL per extract, corresponding to approxi-
mately 0.5–4.2% (w/w) in the dry drug (exhaustive extraction).
Ratios of rosavins to flavonoids (1 þ 2) were 0.30–4.84 (rhi-
zomes) and 0.10–1.54 (roots), while ratios of salidroside to flavo-
noids were found to be in the range of 0.06–4.91 (rhizomes) and
0.01–4.05 (roots).
Although the flavonoids 1 and 2 are also found in other
Rhodiola species, their prevalence, their ratio to each other and
to phenylpropenoids and salidrosides may be useful for quality
testing. Thus, it may give an additional analytical option with an
easily detectable and quantifiable marker for the specification of
R. rosea products for medicinal use. Further research is needed
to confirm occurrence and quantity of 1 and 2, as well as other
flavonoids from other data sets – potentially including other
common Rhodiola species.
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